Bishal Gyawali
Bishal Gyawali
Brigham and Women's Hospital, Harvard Medical School
Verified email at - Homepage
Cited by
Cited by
Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis
B Dhakal, A Szabo, S Chhabra, M Hamadani, A D’Souza, SZ Usmani, ...
JAMA oncology 4 (3), 343-350, 2018
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer
B Gyawali, A Ota, Y Ando
The New England Journal of Medicine 374 (5), 493, 2016
Assessment of the clinical benefit of cancer drugs receiving accelerated approval
B Gyawali, SP Hey, AS Kesselheim
JAMA internal medicine 179 (7), 906-913, 2019
Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer
N Hayashi, Y Ando, B Gyawali, T Shimokata, O Maeda, M Fukaya, H Goto, ...
Oncology reports 35 (3), 1727-1731, 2016
Opioid-induced constipation
B Gyawali, N Hayashi, H Tsukuura, K Honda, T Shimokata, Y Ando
Scandinavian journal of gastroenterology 50 (11), 1331-1338, 2015
Duration of adjuvant trastuzumab in HER2 positive breast cancer: overall and disease free survival results from meta-analyses of randomized controlled trials
B Gyawali, S Niraula
Cancer treatment reviews 60, 18-23, 2017
Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines
TJ Hwang, JM Franklin, CT Chen, JC Lauffenburger, B Gyawali, ...
J Clin Oncol 36 (18), 1805-1812, 2018
Economics of cancer medicines: for whose benefit?
B Gyawali, R Sullivan
The New Bioethics 23 (1), 95-104, 2017
Chemotherapy in locally advanced head and neck squamous cell carcinoma
B Gyawali, T Shimokata, K Honda, Y Ando
Cancer treatment reviews 44, 10-16, 2016
Immunotherapy in non–small-cell lung Cancer patients with performance status 2: clinical decision making with scant evidence
A Passaro, G Spitaleri, B Gyawali, F de Marinis
Journal of Clinical Oncology 37 (22), 1863-1867, 2019
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials
B Gyawali, Y Ando
Annals of Oncology 28 (4), 898-899, 2017
ReDO_DB: the repurposing drugs in oncology database
P Pantziarka, C Verbaanderd, V Sukhatme, IR Capistrano, S Crispino, ...
ecancermedicalscience 12, 2018
Health policy: Me-too drugs with limited benefits—the tale of regorafenib for HCC
B Gyawali, V Prasad
Nature Reviews Clinical Oncology 14 (11), 653-654, 2017
Association between progression‐free survival and patients’ quality of life in cancer clinical trials
TJ Hwang, B Gyawali
International journal of cancer 144 (7), 1746-1751, 2019
A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with pd-1 inhibitors: a meta-analysis of correlation and …
B Gyawali, SP Hey, AS Kesselheim
JAMA network open 1 (2), e180416-e180416, 2018
Muscle wasting associated with the long-term use of mTOR inhibitors
B Gyawali, T Shimokata, K Honda, C Kondoh, N Hayashi, Y Yoshino, ...
Molecular and clinical oncology 5 (5), 641-646, 2016
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
S Niraula, B Gyawali
Breast cancer research and treatment 173 (1), 103-109, 2019
Reporting harms more transparently in trials of cancer drugs
B Gyawali, T Shimokata, K Honda, Y Ando
Bmj 363, k4383, 2018
The US Food and Drug Administration’s approval of adjuvant sunitinib for renal cell cancer: a case of regulatory capture?
B Gyawali, DA Goldstein
JAMA oncology 4 (5), 623-624, 2018
Real-world evidence and randomized studies in the precision oncology era: the right balance
B Gyawali, S Parsad, BA Feinberg, C Nabhan
JCO Precision Oncology 1, 1-5, 2017
The system can't perform the operation now. Try again later.
Articles 1–20